About
About Galaxy Biomedical Investment Co., Ltd
Galaxy Biomedical Investment Co., Ltd. operates in the transmission and distribution, electronic information, and bio-pharmaceutical industries in China. It operates through five segments: Power Transmission And Transformation, Electronic Components, Software, Biomedicine, and Others. The company offers rectifier, power, dry-type, distribution, and other small and medium-sized transformers for use in non-ferrous metal smelting, petrochemical, electrochemistry, new energy, and power grid companies; and displacement sensors, radio frequency components, resistors, and potentiometers. It also engages in the operation and maintenance, software sales, and network engineering activities; and agency product sales, and research and development services. In addition, the company engages in the research and development of drugs, such as immune cells, monoclonal antibodies, stem cells, and oncolytic viruses for the treatment of tumors. It also exports its products. The company was formerly known as Beihai Yinhe Industry Investment Co., Ltd. and changed its name to Galaxy Biomedical Investment Co., Ltd. in October 2015. Galaxy Biomedical Investment Co., Ltd. was founded in 1993 and is headquartered in Beihai, China.
Visit company website
5 years, 5 months ago
Galaxy Biomedical Investment Co., Ltd is currently in a long term uptrend where the price is trading 64.1% above its 200 day moving average.
From a valuation standpoint, the stock is 72.6% cheaper than other stocks from the Technology sector with a price to sales ratio of 2.2.
Galaxy Biomedical Investment Co., Ltd's total revenue rose by 72.5% to $307M since the same quarter in the previous year.
Its net income has increased by 814.4% to $40M since the same quarter in the previous year.
Finally, its free cash flow fell by 156.8% to $-28M since the same quarter in the previous year.
Based on the above factors, Galaxy Biomedical Investment Co., Ltd gets an overall score of 4/5.